Enabling the industrialization of human induced pluripotent stem cell-based therapies
On demand

Enabling the industrialization of human induced pluripotent stem cell-based therapies

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Enabling the industrialization of human induced pluripotent stem cell-based therapies

Human induced pluripotent stem cells (iPSCs) offer a promising and unlimited source of cells for curative cell replacement therapies in the treatment of devastating diseases such as Parkinson’s disease (PD) and diabetes.

However, in order to commercialize these therapies to treat a large number of individuals at affordable costs, it is necessary to demonstrate the safety and efficacy of these therapies and industrialize the manufacturing process for iPSC-derived functional cells in a scalable and controlled manner.

This webinar provides a checklist of the major steps we have taken at Lonza towards the industrialization of iPSC-derived cell therapy products with focus on the development of a current Good Manufacturing Practice (cGMP)-compliant iPSC manufacturing process, characterization of iPSCs, development of scalable, computer-controlled bioprocessing system for expansion and / or directed differentiation of human iPSC using microcarrier-based and carrier-free strategies.

Key learning points include:

  • Identifying the main manufacturing challenges for generation, expansion, and directed differentiation of human iPSC-based cell therapies
    Highlighting the current status of the field concerning scalability, cell culture format (2D versus 3D), automation, characterization of human iPSCs, and fairly complicated directed differentiation process
  • Tracking development of a cGMP-compliant iPSC manufacturing process that supports efficient and unbiased directed differentiation processes into all three main germ layers
    Focusing on the development of a current Good Manufacturing Practice (cGMP)-compliant iPSC manufacturing process, establishing a comprehensive iPSC characterization platform, and development of unbiased proprietary cell culture system , L7TM that allows directed differentiation of iPSCs into all three embryonic germ-layers including ectoderm, endoderm, and mesoderm
  • Establishing an end-to-end platform allowing a large-scale expansion of high quality human iPSCs to support the required cell demand for various clinical indications
    Demonstrating how we use a microcarrier-based technology to establish a closed, automated and scalable stirred tank bioreactor platform, capable of sustaining high fold expansion of high quality human iPSCs. We demonstrate that human iPSCs can be expanded, released from the microcarriers and concentrated in a fully closed manner. Harvested cells could be directly inoculated into a subsequent expansion or differentiation process, or cryopreserved as a high cell density seed bank for use in future, large-scale bioprocesses
  • Incorporating best bioprocessing practices for the development of carrier-free, scalable manufacturing processes for generation of high-quality iPSC derivatives under 3D computer-controlled bioreactor conditions
    We report how we incorporated an innovative technique using computational fluid dynamics (CFD) modeling to effectively scale-up iPSC-based manufacturing processes in a serum-free and carrier-free 3 L computer-controlled bioreactor system in a relatively efficient manner. We also highlight a proof-of-concept directed differentiation process for aggregate-based iPSCs in 3 L bioreactor in a relatively efficient manner
  • Addressing one of the key quality characteristics of human iPSCs and evaluation of the long-term cellular and genomic stability of Lonza GMP compliant iPSC lines
    We show that three human iPSC lines generated and banked five years ago using our proprietary cGMP manufacturing process can be thawed, expanded, characterized, and directly differentiated into the cells from three germ layers

The Lonza logo is a Lonza Ltd. Trademark

Krishna Panchalingam
Krishna Panchalingam
Bioprocess Scientist at Lonza Pharma & Biotech

Dr. Panchalingam is a Senior Scientist in the Cell and Gene Therapy Process Development group, Emerging Technologies at Lonza. He has over 14 years of experience in stem cell bioengineering, bioprocessing and in the cell and gene therapy field. Dr. Panchalingam holds a PhD degree in Chemical Engineering from the University of Calgary (Calgary, Canada) where he focused on the development of viable, scalable, and defined bioprocesses in the field of regenerative medicine.

After completing his PhD, Dr. Panchalingam started as a Bioprocess Scientist/Engineer at CCRM (Toronto, Canada), leading the development and optimization of large-scale immune cell and iPSC-based manufacturing processes and the controlled differentiation of iPSCs to cardiomyocytes.

Since joining Lonza in 2016, Dr. Panchalingam has been leading the development of new technologies and robust manufacturing processes for the clinical manufacturing of next generation cell and gene therapies.

Inbar Friedrich Ben-Nun
Inbar Friedrich Ben-Nun
Senior Manager at Lonza

Dr. Inbar Friedrich Ben-Nun is a Sr. Manager in the Cell and Gene Therapy R&D at Lonza. Inbar obtained her PhD in Molecular and Structural Biochemistry at the Hebrew University of Jerusalem. As a postdoctoral fellow at the Scripps Research Institute, CA, she acquired extensive experience with pluripotent stem cells. Her work published in “Nature Methods” showed for the first time that stem cell research could be apply to save species from extinction.

Inbar has joined Lonza in 2011, and in her current role she leads a team that focuses on developing innovative solutions to enable stem cell-based therapies.

Marcos Langtry
Marcos Langtry
Head of Allogeneic Cell Therapy - Commercial Development at Lonza Pharma & Biotech

Marcos Langtry is Head of Allogeneic Cell Therapy Commercial Development at Lonza Pharma & Biotech. He is responsible for the allogeneic commercial strategy, current and future offerings, and portfolio optimization. Before joining Lonza, Marcos held several senior level positions at TiGenix, Astra Zeneca and Sanofi in the areas of external manufacturing, process development, technical operations and industrial strategy; where he acquired extensive experience with aseptically filled, biologic and cell therapy products.

Marcos Langtry holds a Master´s degree in Biochemical Engineering from University College London (UK) and an MBA from Imperial College London (UK). He is also qualified as Chartered Engineer (CEng) and Chartered Scientist (CSci).